Abstract #3585

MRI assessment of spatial distribution of hypoxia in pre-clinical xenograft models of non-small cell lung cancer via GdDO3NI: A Novel Hypoxia-Binding T1 Contrast Agent

Shubhangi Agarwal¹, Nutandev B Jayadev¹, Carlos Renteria¹, Xiangxing Kong², Yanqing Tian^2,3, Landon J Inge⁴, and Vikram D Kodibagkar¹

¹Arizona State University, Tempe, AZ, United States, ²Biodesign Institute, Arizona State University, Tempe, AZ, United States, ³Department of Materials Science and Engineering, South University of Science and Technology of China, Shenzhen, People's Republic of China, ⁴Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States

Degree of tumor hypoxia and its spatial distribution could impact the therapeutic choices and lead to development of improved treatment plans. This study uses a hypoxia binding T1 contrast agent GdDO3NI, to evaluate the dependence of hypoxia activated pro-drug TPZ (Tirapazamine) on baseline tumor oxygenation and its effect on the oxygenation of two non-small cell lung cancer lines ( NCI-H1975 and patient derived xenograft M112004). GdDO3NI was able to report the changes in hypoxia distribution in the tumor models in response to Tirapazamine therapy and correlation with therapeutic effect.

This abstract and the presentation materials are available to members only; a login is required.

Join Here